Increasing Prevalence Of Fungal Infections Fueling The Growth Of The Market Due To Rising Immunocompromised Population And Poor Hygiene: A Significant Driver Propelling The Dermatomycoses Market In 2025

The Dermatomycoses Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Dermatomycoses Market Size and Projected Growth Rate?
In recent years, the dermatomycoses market has seen significant expansion. It is predicted to increase from $14.12 billion in 2024 to $14.95 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%. The growth observed in the historical period can be attributed to several factors including the advancement in antifungal treatments, increasing occurrence of fungal infections, growth in awareness regarding skin health, enhancing improved diagnostic techniques, and the proliferation of over-the-counter antifungal products.

Expectations are high for a significant increase in the dermatomycoses market size over the coming years. The prediction is that it will have escalated to an impressive $18.59 billion by 2029, with a compound annual growth rate (CAGR) of 5.6%. Factors contributing to this projected growth include the ageing population, escalation in drug-resistant fungal strains, mounting preference for organic and natural antifungal items, advanced biotechnology and antifungal research, and increased access to healthcare in developing areas. The forecast period is expected to see notable trends such as innovative antifungal drug development, advances in quick diagnostic technology, the incorporation of artificial intelligence in dermatology, the use of nanotechnology in antifungal treatments, and innovations in microbiome-based therapies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21934

What Are the Major Segments in the Dermatomycoses Market?
The dermatomycoses market covered in this report is segmented -

1) By Drugs: Corticosteroids, Corticosteroid-Sparing Agents, Immunosuppressive, Immunomodulator, Antifungals, Other Drugs
2) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administration
3) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegmentss:

1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Corticosteroid-Sparing Agents: Tacrolimus, Pimecrolimus
3) By Immunosuppressive: Methotrexate, Azathioprine, Cyclophosphamide
4) By Immunomodulator: Interferon-Gamma, Thalidomide
5) By Antifungals: Topical Antifungals, Oral Antifungals, Systemic Antifungals
6) By Other Drugs: Antihistamines, Antibacterial Agents

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21934&type=smp

What Are The Driving Dermatomycoses Market Evolution?
The dermatomycoses market is expected to flourish due to the escalating cases of fungal infections. These infections, which affect the skin, nails, hair, or even internal organs, lead to various health problems. Extensive use of broad-spectrum antibiotics can disturb the natural microbiome, enabling fungi to proliferate and initiate infections. This imbalance weakens the body's natural defense and makes people prone to opportunistic fungal infections. Dermatomycoses, triggered by dermatophytes, yeasts, and molds, are responsible for many superficial and systemic fungal diseases, affecting many tissues. For instance, in November 2023, the UK Health Security Agency reported that worldwide, there is an annual incidence of about 6.5 million invasive fungal infections, leading to nearly 3.8 million deaths, with 2.5 million directly linked to these infections. Consequently, the growing occurrence of fungal infections is stimulating the dermatomycoses market. The dermatomycoses market is also likely to be driven by a surge in demand for oral drugs, given their accessibility and effectiveness. Oral medications, including tablets, capsules, or liquids that are ingested and absorbed through the digestive system, are increasingly desirable as they offer comfort and efficiency over injections or alternate delivery methods. Dermatomycoses support oral medications since systemic antifungal agents can enter the infected skin, hair, or nails via blood circulation, promising deeper and extended treatment versus topical applications. For example, in October 2022, the Centers for Disease Control and Prevention recorded a 57% increase in the provision of oral antivirals, rising from 643 per 100,000 persons between April 24 and May 21, 2022, to 1,012 per 100,000 persons between July 31 and August 28, 2022. Therefore, the escalating demand for oral drugs contributes to the expansion of the dermatomycoses market.

Which Firms Dominate The Dermatomycoses Market Segments?
Major companies operating in the dermatomycoses market are Pfizer Inc., Bayer AG, Saphnix Life Sciences, MITS Healthcare Private Limited, Weefsel Pharma, AdvaCare Pharma, Associated Biotech, Healthy Life Pharma Private Limited, Blueberry Therapeutics Ltd., Livealth Biopharma Pvt. Ltd., LGM Pharma, SiNi Pharma Pvt. Ltd., Joshi Agrochem Pharma Private Limited, Wellona Pharma, Abiba Pharmacia Pvt. Ltd., Vee Excel Drugs & Pharmaceuticals Pvt. Ltd., Femcorp Pharma, Lexicare Pharma Pvt. Ltd., Glamris Dermacare, Henin Lukinz

What Trends Are Expected to Dominate the Dermatomycoses Market in the Next 5 Years?
Significant players in the dermatomycoses industry are turning their attention to experimental new drug candidates as a way to advance treatment for onychomycosis and improve its effectiveness. An experimental new drug (IND) candidate is simply a medicinal compound being tested in preclinical or clinical studies to gauge its safety, effectiveness, and the likelihood of it gaining regulatory approval before becoming an officially authorized treatment. In particular, Vanda Pharmaceuticals Inc., a biopharmaceutical firm based in the US, received US Food and Drug Administration (FDA) approval for their Investigational New Drug VTR-297 candidate for treating onychomycosis in January 2024. VTR-297 stands out among topical antifungal candidates due to its histone deacetylase (HDAC) inhibitor properties, setting it apart from conventional antifungal therapies. The drug works by tackling the root of fungal growth, demonstrating significant antifungal activity against dermatophytes and other fungi. This ground-breaking approach potentially offers quicker and more effective treatment results, while also mitigating the risk of recurring infections, thus addressing a pressing unmet need in onychomycosis treatment.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/dermatomycoses-global-market-report

Which Is The Largest Region In The Dermatomycoses Market?
North America was the largest region in the dermatomycoses market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatomycoses market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Dermatomycoses Market?
2. What is the CAGR expected in the Dermatomycoses Market?
3. What Are the Key Innovations Transforming the Dermatomycoses Industry?
4. Which Region Is Leading the Dermatomycoses Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.